Top 5 Oncology Articles in 2023
This year's top oncology news included a study that suggested low-fat meals could affect blood concentration levels, and high blood concentration has been associated with a better response to the drug, Alecensa.
- For Alecensa, ‘Take With Meal’ May Have a Caveat
Study suggests that low-fat meals may affect blood concentration levels, and high blood concentration has been correlated with a better response to the drug.
Read here - ‘Thrilling’ Finding: Daily Tagrisso Halves Risk of Death in Some Lung Cancer Patients
Findings from the ADAURA trial argue for starting treatment with the AstraZeneca drug early, says Yale’s Roy Herbst, M.D., Ph.D., the principal investigator.
Read here - Looking Out for the Ocular Side Effects of the Immune Checkpoint Inhibitors
Side effects from Opdivo, Yervoy and Keytruda that affect the eyes are relatively rare but can be serious. A recent review identified 290 cases.
Read here - Esophageal Cancer Update
Gastroesophageal reflux disease is a risk factor for what is now the more common type of esophageal cancer, adenocarcinoma. Immunotherapy is coming on strong as a treatment.
Read here - Is Medicare Advantage a Disadvantage For Patients With Cancer?
Medicare Advantage plans have been associated with increased screening rates. But managed care tactics and narrow networks may be a disadvantage for people needing care.
Read here
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
